James Bridges, MD
Internal Medicine · Hot Springs, ARNPI 1821037060
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,480 and has fallen 56.0% since, to $651 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$897
- GSK$867
- AbbVie$800
- Pfizer$463
- Lilly USA, LLC$389
- Amgen$265
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,363100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $897 |
| GSK | 66 | $867 |
| AbbVie | 61 | $800 |
| Pfizer | 36 | $463 |
| Lilly USA, LLC | 28 | $389 |
| Amgen(2 entities) | 17 | $265 |
| Dexcom, Inc. | 10 | $173 |
| Boehringer Ingelheim | 8 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $136 |
| Novo Nordisk | 8 | $122 |
| Sunovion Pharmaceuticals Inc. | 9 | $109 |
| Esperion Therapeutics, Inc. | 6 | $101 |
| Astellas Pharma US Inc | 6 | $101 |
| Abbott | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Bayer | 4 | $65 |
| Novartis | 4 | $58 |
| Nestle Healthcare Nutrition Inc. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $40 |
| Merck | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Corium, LLC | 1 | $19 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Globus Medical | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,363 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $120,808 |
| EliquisApixaban | 84 | $78,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $45,923 |
| FarxigaDapagliflozin Propanediol | 43 | $43,918 |
| JardianceEmpagliflozin | 37 | $43,106 |
| XareltoRivaroxaban | 55 | $40,975 |
| RexultiBrexpiprazole | 20 | $38,907 |
| MounjaroTirzepatide | 31 | $37,488 |
| JanuviaSitagliptin Phosphate | 31 | $36,902 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,099 |
| LinzessLinaclotide | 24 | $14,850 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $14,281 |
| InvokanaCanagliflozin | 22 | $13,473 |
| MyrbetriqMirabegron | 16 | $11,861 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $122 | $120,80894 claims |
| PfizerEliquis | $463 | $78,40284 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $897 | $66,46997 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $867 | $57,48684 claims |
| Johnson & JohnsonXarelto, Invokana | $40 | $54,44877 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $144 | $49,00549 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $75 | $38,90720 claims |
| Lilly USA, LLCMounjaro | $389 | $37,48831 claims |
| MerckJanuvia | $33 | $36,90231 claims |
| AbbVieLinzess | $800 | $14,85024 claims |
| Astellas Pharma US IncMyrbetriq | $101 | $11,86116 claims |
| NovartisEntresto | $58 | $8,12212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Hot Springs
- Jenny NavarroHot Springs$11K
- Seth BarnesHot Springs$9K
- Gregory WhortonHot Springs$5K
- David PyleJonesboro$93K
- Aaron StrobelLittle Rock$32K
- Stuart BensonRogers$24K
- Purnima SarkarEarle$21K
- John NorwoodJonesboro$21K
- Ahmed AliConway$18K
- Jeremy DavisLittle Rock$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.